Novel CAR-T therapy sees success in treatment-resistant myeloma patients

Written by Harriet Wall

Idecabtagene vicleucel (ide-cel), a novel CAR-T therapy, has produced positive results in a Phase II trial against multiple myeloma. The multi-institutional study, led by scientists from the Dana-Farber Cancer Institute (MA, USA), has led to remissions in almost 75% of patients who had previously relapsed. These results are significantly better than those seen in currently available therapies. Their results were recently published in the journal, New England Journal of Medicine. “Despite numerous advances in the treatment of multiple myeloma, relapses are common. Patients whose disease continues to worsen after receiving standard therapy have relatively few treatment options that provide high...

To view this content, please register now for access

It's completely free